Morgan-Hughes J A, Sweeney M G, Cooper J M, Hammans S R, Brockington M, Schapira A H, Harding A E, Clark J B
University Department of Clinical Neurology, Institute of Neurology, London, UK.
Biochim Biophys Acta. 1995 May 24;1271(1):135-40. doi: 10.1016/0925-4439(95)00020-5.
This study examines the relationship of genotype to phenotype in 14 unselected patients who were found to harbour the A3243G transition in the mitochondrial transfer RNALeu(UUR) gene commonly associated with the syndrome of mitochondrial encephalopathy, lactic acidosis and strokes (MELAS). Only 6 of the 14 cases (43%) had seizures and recurrent strokes, the core clinical features of the MELAS phenotype. Of the remaining cases, four had an encephalomyopathy with deafness, ataxia and dementia, two had syndromes with progressive external ophthalmoplegia and two had limb weakness alone. Even within the MELAS subgroup, the majority of patients had one or more clinical manifestations considered to be atypical of the MELAS syndrome. They included developmental delay, ophthalmoparesis, pigmentary retinopathy and intestinal pseudo-obstruction. The proportion of mutant mitochondrial DNA (mtDNA) in muscle was generally higher in patients with recurrent strokes than in those without strokes, the highest levels being observed in MELAS cases with early onset disease. Studies of isolated muscle mitochondria identified a range of respiratory chain abnormalities mostly involving Complex I; immunoblots of Complex I in 3 of 10 cases showed selective loss of specific subunits encoded by nuclear genes. In the group as a whole, however, no clear correlations were observed between the severity or extent of the respiratory chain abnormality and clinical phenotype or the proportion of mutant mtDNA in biopsied skeletal muscle. These discrepancies suggest that, in patients harbouring the common MELAS3243 mutation, differences in heteroplasmy and the proportions of mutant mtDNA may not be the sole determinants of disease expression and that additional genetic mechanisms are involved in defining the range of clinical and biochemical phenotypes associated with this aberrant mitochondrial genome.
本研究调查了14例未经过挑选的患者的基因型与表型之间的关系,这些患者被发现线粒体亮氨酸转运RNA(UUR)基因存在A3243G转换,该转换通常与线粒体脑肌病伴乳酸酸中毒和卒中综合征(MELAS)相关。14例患者中只有6例(43%)出现癫痫发作和复发性卒中,这是MELAS表型的核心临床特征。其余病例中,4例患有伴有耳聋、共济失调和痴呆的脑肌病,2例患有伴有进行性眼外肌麻痹的综合征,2例仅出现肢体无力。即使在MELAS亚组中,大多数患者也有一个或多个被认为是MELAS综合征非典型的临床表现。这些表现包括发育迟缓、眼肌麻痹、色素性视网膜病变和肠道假性梗阻。复发性卒中患者肌肉中突变线粒体DNA(mtDNA)的比例通常高于无卒中患者,在疾病早发的MELAS病例中观察到最高水平。对分离的肌肉线粒体的研究发现了一系列呼吸链异常,主要涉及复合体I;10例中的3例复合体I免疫印迹显示由核基因编码的特定亚基选择性缺失。然而,在整个研究组中,未观察到呼吸链异常的严重程度或范围与临床表型或活检骨骼肌中突变mtDNA比例之间存在明确的相关性。这些差异表明,在携带常见MELAS3243突变的患者中,异质性和突变mtDNA比例的差异可能不是疾病表达的唯一决定因素,并且在定义与这种异常线粒体基因组相关的临床和生化表型范围时还涉及其他遗传机制。